Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Market Chatter: Electronic Arts Takes Dispute With Bondholders to Court

Market Chatter: Electronic Arts Takes Dispute With Bondholders to Court

MT newswireMT newswire2026/11/04 17:43
01:43 PM EST, 11/04/2026 (MT Newswires) -- Electronic Arts (EA) has filed a lawsuit against its bondholders' trustee US Bank Trust, asking a federal judge to declare it isn't in default and doesn't owe a change-of-control premium, Bloomberg reported Wednesday. The company, which was taken private in August by Saudi Arabia's investment fund, said in the suit that any effort to seek an early payment of a premium would cause it "serious irreparable harm" and could trigger cross-default provisions under about $18 billion in debt of its parent, Oak-Eagle AcquireCo, the report said. Electronic Arts said no premium is owed because the notes were rated investment grade by Egan-Jones Ratings and because of a defeasance maneuver it invoked in a February buyback proposal, according to the report. Electronic Arts and US Bank did not immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12